4D Molecular Therapeutics Key Executives
This section highlights 4D Molecular Therapeutics's key executives, including their titles and compensation details.
Find Contacts at 4D Molecular Therapeutics
(Showing 0 of )
4D Molecular Therapeutics Earnings
This section highlights 4D Molecular Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
$2.89
Stock Price
$133.58M
Market Cap
227
Employees
EmeryVille, CA
Location
Financial Statements
Access annual & quarterly financial statements for 4D Molecular Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $37.00K | $20.72M | $3.13M | $18.04M | $13.61M |
| Cost of Revenue | $- | $97.10M | $3.88M | $3.02M | $53.04M |
| Gross Profit | $37.00K | $-76.37M | $-751.00K | $15.02M | $-39.43M |
| Gross Profit Ratio | 100.00% | -368.50% | -24.00% | 83.30% | -289.64% |
| Research and Development Expenses | $141.30M | $97.10M | $80.25M | $61.36M | $53.04M |
| General and Administrative Expenses | $46.58M | $36.49M | $32.91M | $28.01M | $17.24M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $46.58M | $36.49M | $32.91M | $28.01M | $17.24M |
| Other Expenses | $- | $- | $2.54M | $16.00K | $-181.00K |
| Operating Expenses | $187.88M | $133.59M | $113.16M | $89.37M | $70.28M |
| Cost and Expenses | $187.88M | $133.59M | $113.16M | $89.37M | $70.28M |
| Interest Income | $27.05M | $12.21M | $2.57M | $137.00K | $152.00K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $5.75M | $3.88M | $3.02M | $1.44M |
| EBITDA | $-187.84M | $-107.12M | $-106.15M | $-68.31M | $-55.22M |
| EBITDA Ratio | -507678.38% | -516.90% | -3393.00% | -395.46% | -405.68% |
| Operating Income | $-187.84M | $-112.87M | $-110.03M | $-71.33M | $-56.66M |
| Operating Income Ratio | -507678.38% | -544.65% | -3516.52% | -395.46% | -416.28% |
| Total Other Income Expenses Net | $26.97M | $12.03M | $2.54M | $16.00K | $-29.00K |
| Income Before Tax | $-160.87M | $-100.84M | $-107.49M | $-71.32M | $-56.69M |
| Income Before Tax Ratio | -434778.38% | -486.59% | -3435.41% | -395.37% | -416.49% |
| Income Tax Expense | $- | $- | $-6.42M | $-3.02M | $-152.00K |
| Net Income | $-160.87M | $-100.84M | $-101.08M | $-68.30M | $-56.54M |
| Net Income Ratio | -434778.38% | -486.59% | -3230.30% | -378.63% | -415.38% |
| EPS | $-2.98 | $-2.58 | $-3.12 | $-2.46 | $-2.12 |
| EPS Diluted | $-2.98 | $-2.58 | $-3.12 | $-2.46 | $-2.12 |
| Weighted Average Shares Outstanding | 53.94M | 39.13M | 32.35M | 27.73M | 26.68M |
| Weighted Average Shares Outstanding Diluted | 53.94M | 39.13M | 32.35M | 27.73M | 26.68M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00K | $3.00K | $5.00K | $28.00K | $-19.00K | $20.20M | $239.00K | $298.00K | $1.25M | $500.00K | $162.00K | $1.22M | $92.00K | $1.37M | $14.58M | $2.00M | $-977.00K | $7.42M | $3.63M | $3.54M |
| Cost of Revenue | $-3.22M | $- | $1.62M | $1.59M | $4.24M | $1.40M | $1.43M | $1.41M | $1.39M | $879.00K | $831.00K | $782.00K | $1.89M | $15.84M | $15.22M | $12.77M | $12.61M | $11.55M | $15.72M | $13.16M |
| Gross Profit | $3.22M | $3.00K | $-1.62M | $-1.57M | $-4.25M | $18.81M | $-1.19M | $-1.11M | $-141.00K | $-379.00K | $-669.00K | $437.00K | $-1.79M | $-14.47M | $-643.00K | $-10.77M | $-13.58M | $-4.13M | $-12.09M | $-9.62M |
| Gross Profit Ratio | 321900.00% | 100.00% | -32380.00% | -5592.90% | 22394.70% | 93.10% | -497.50% | -373.80% | -11.30% | -75.80% | -413.00% | 35.80% | -1951.10% | -1059.60% | -4.40% | -538.50% | 1390.17% | -55.71% | -332.70% | -272.22% |
| Research and Development Expenses | $43.09M | $38.48M | $31.86M | $27.87M | $26.03M | $25.07M | $23.58M | $22.41M | $21.50M | $18.94M | $20.42M | $19.38M | $17.53M | $15.84M | $15.22M | $12.77M | $12.61M | $11.55M | $15.72M | $13.16M |
| General and Administrative Expenses | $13.03M | $12.65M | $10.60M | $10.29M | $10.61M | $9.11M | $8.79M | $7.99M | $8.47M | $8.05M | $8.17M | $8.23M | $7.33M | $8.19M | $6.95M | $5.54M | $6.84M | $3.68M | $3.06M | $3.65M |
| Selling and Marketing Expenses | $1.59M | $- | $- | $-1.59M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $14.63M | $12.65M | $10.60M | $8.70M | $10.61M | $9.11M | $8.79M | $7.99M | $8.47M | $8.05M | $8.17M | $8.23M | $7.33M | $8.19M | $6.95M | $5.54M | $6.84M | $3.68M | $3.06M | $3.65M |
| Other Expenses | $10.00K | $- | $- | $-10.00K | $-11.00K | $-158.00K | $2.52M | $1.42M | $3.00K | $9.00K | $- | $-46.00K | $-7.00K | $-13.00K | $- | $-101.00K | $-129.00K | $-21.00K | $-18.00K | $-13.00K |
| Operating Expenses | $57.71M | $51.13M | $42.46M | $36.57M | $36.63M | $34.18M | $32.38M | $30.40M | $29.97M | $27.00M | $28.59M | $27.61M | $24.86M | $24.03M | $22.18M | $18.31M | $19.45M | $15.24M | $18.78M | $16.81M |
| Cost and Expenses | $56.12M | $51.13M | $42.46M | $38.16M | $36.63M | $34.18M | $32.38M | $30.40M | $29.97M | $27.00M | $28.59M | $27.61M | $24.86M | $24.03M | $22.18M | $18.31M | $19.45M | $15.24M | $18.78M | $16.81M |
| Interest Income | $6.47M | $7.29M | $7.55M | $5.75M | $4.38M | $3.88M | $2.51M | $1.44M | $1.34M | $795.00K | $340.00K | $100.00K | $- | $435.00K | $7.00K | $7.00K | $4.00K | $4.00K | $14.00K | $130.00K |
| Interest Expense | $- | $- | $- | $- | $1.41M | $- | $- | $- | $- | $795.00K | $340.00K | $100.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $-4.92M | $1.70M | $1.62M | $1.59M | $1.51M | $1.40M | $1.43M | $1.41M | $1.39M | $879.00K | $831.00K | $782.00K | $1.89M | $382.00K | $370.00K | $381.00K | $371.00K | $369.00K | $359.00K | $344.00K |
| EBITDA | $-61.04M | $-49.43M | $-40.83M | $-36.54M | $-35.14M | $-12.58M | $-30.71M | $-28.69M | $-27.33M | $-25.62M | $-27.59M | $-25.61M | $-22.88M | $-22.28M | $-7.23M | $-15.93M | $-20.05M | $-7.45M | $-14.79M | $-12.93M |
| EBITDA Ratio | -6103800.00% | -1647633.33% | -816640.00% | -130507.14% | 184942.11% | -62.25% | -12849.00% | -9629.00% | -2191.82% | -5123.20% | -17033.95% | -2100.90% | -24866.30% | -1630.97% | -49.56% | -796.55% | 2052.30% | -100.35% | -407.10% | -365.86% |
| Operating Income | $-56.12M | $-51.13M | $-42.46M | $-38.14M | $-36.65M | $-13.97M | $-32.14M | $-30.11M | $-28.72M | $-26.50M | $-28.43M | $-26.39M | $-24.76M | $-22.66M | $-7.60M | $-16.31M | $-20.42M | $-7.82M | $-15.15M | $-13.28M |
| Operating Income Ratio | -507678.38% | -1704400.00% | -849120.00% | -136200.00% | 192905.26% | -69.16% | -13446.03% | -10102.68% | -2303.13% | -5299.00% | -17546.91% | -2165.05% | -26917.39% | -1658.93% | -52.10% | -815.60% | 2090.28% | -105.32% | -416.98% | -375.59% |
| Total Other Income Expenses Net | $6.45M | $7.29M | $7.50M | $5.74M | $4.37M | $3.72M | $2.52M | $1.42M | $1.34M | $804.00K | $340.00K | $54.00K | $-319.00K | $422.00K | $7.00K | $-94.00K | $-125.00K | $-17.00K | $-4.00K | $117.00K |
| Income Before Tax | $-49.67M | $-43.84M | $-34.95M | $-32.40M | $-32.28M | $-10.26M | $-29.62M | $-28.68M | $-27.38M | $-25.69M | $-28.09M | $-26.34M | $-25.08M | $-22.24M | $-7.59M | $-16.41M | $-20.55M | $-7.83M | $-15.15M | $-13.16M |
| Income Before Tax Ratio | -434778.38% | -1461433.33% | -699060.00% | -115717.86% | 169910.53% | -50.76% | -12391.63% | -9624.83% | -2195.59% | -5138.20% | -17337.04% | -2160.62% | -27264.13% | -1628.04% | -52.05% | -820.30% | 2103.07% | -105.55% | -417.09% | -372.28% |
| Income Tax Expense | $1 | $- | $- | $-1 | $6.73M | $-3.88M | $-1.43M | $-1.42M | $-106.00K | $-1.60M | $-680.00K | $-154.00K | $312.00K | $-435.00K | $- | $-7.00K | $-4.00K | $-4.00K | $-14.00K | $-130.00K |
| Net Income | $-49.67M | $-43.84M | $-34.95M | $-32.40M | $-32.28M | $-10.26M | $-29.62M | $-27.26M | $-27.27M | $-24.09M | $-27.41M | $-26.18M | $-25.08M | $-22.24M | $-7.59M | $-16.41M | $-20.55M | $-7.83M | $-15.15M | $-13.16M |
| Net Income Ratio | -434778.38% | -1461433.33% | -699060.00% | -115717.86% | 169910.53% | -50.76% | -12391.63% | -9146.98% | -2187.09% | -4818.40% | -16917.28% | -2147.99% | -27264.13% | -1628.04% | -52.05% | -820.30% | 2103.07% | -105.55% | -417.09% | -372.28% |
| EPS | $-0.90 | $-0.79 | $-0.63 | $-0.66 | $-0.83 | $-0.24 | $-0.77 | $-0.83 | $-0.84 | $-0.74 | $-0.85 | $-0.81 | $-0.93 | $-0.82 | $-0.28 | $-0.61 | $-0.77 | $-0.36 | $-1.02 | $-0.89 |
| EPS Diluted | $-0.90 | $-0.79 | $-0.63 | $-0.66 | $-0.83 | $-0.24 | $-0.77 | $-0.83 | $-0.84 | $-0.74 | $-0.85 | $-0.81 | $-0.93 | $-0.82 | $-0.28 | $-0.61 | $-0.77 | $-0.36 | $-1.02 | $-0.89 |
| Weighted Average Shares Outstanding | 53.94M | 55.55M | 55.28M | 49.27M | 39.13M | 42.26M | 38.34M | 32.72M | 32.49M | 32.39M | 32.28M | 32.23M | 27.02M | 27.02M | 26.74M | 26.69M | 26.68M | 21.60M | 14.84M | 14.84M |
| Weighted Average Shares Outstanding Diluted | 53.94M | 55.55M | 55.28M | 49.27M | 39.13M | 42.26M | 38.34M | 32.72M | 32.49M | 32.39M | 32.32M | 32.23M | 27.02M | 27.02M | 26.74M | 26.69M | 26.69M | 21.60M | 14.84M | 14.84M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $149.34M | $249.11M | $218.64M | $315.43M | $276.73M |
| Short Term Investments | $275.54M | $39.12M | $161.20M | $94.78M | $- |
| Cash and Short Term Investments | $424.88M | $288.23M | $218.64M | $315.43M | $276.73M |
| Net Receivables | $- | $- | $- | $47.00K | $1.49M |
| Inventory | $- | $- | $-5.79M | $-8.50M | $- |
| Other Current Assets | $10.05M | $8.36M | $6.96M | $8.46M | $8.89M |
| Total Current Assets | $434.93M | $296.59M | $220.51M | $315.43M | $282.66M |
| Property Plant Equipment Net | $40.61M | $31.66M | $35.35M | $28.95M | $5.07M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $10.95M | $4.91M | $67.65M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $84.84M | $684.00K | $1.08M | $-58.55M | $602.00K |
| Total Non-Current Assets | $125.45M | $43.30M | $41.34M | $38.06M | $5.67M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $560.38M | $339.89M | $261.85M | $353.49M | $288.33M |
| Account Payables | $4.39M | $3.52M | $3.32M | $4.76M | $1.79M |
| Short Term Debt | $5.64M | $3.15M | $5.31M | $2.46M | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $257.00K | $273.00K | $884.00K | $2.60M | $6.59M |
| Other Current Liabilities | $18.87M | $12.01M | $6.74M | $9.03M | $8.37M |
| Total Current Liabilities | $29.15M | $18.95M | $15.73M | $16.34M | $16.74M |
| Long Term Debt | $18.97M | $11.52M | $13.47M | $15.22M | $- |
| Deferred Revenue Non-Current | $- | $972.00K | $1.08M | $2.49M | $13.23M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.66M | $617.00K | $233.00K | $334.00K | $1.97M |
| Total Non-Current Liabilities | $20.63M | $13.11M | $14.78M | $18.04M | $15.20M |
| Other Liabilities | $- | $- | $- | $526.10M | $- |
| Total Liabilities | $49.78M | $32.06M | $30.51M | $560.48M | $31.94M |
| Preferred Stock | $- | $- | $- | $- | $288.33M |
| Common Stock | $5.00K | $4.00K | $3.00K | $3.00K | $3.00K |
| Retained Earnings | $-576.20M | $-415.33M | $-314.49M | $-207.00M | $-135.68M |
| Accumulated Other Comprehensive Income Loss | $- | $16.00K | $-1.20M | $-423.00K | $-288.33M |
| Other Total Stockholders Equity | $1.09B | $723.14M | $547.02M | $526.52M | $103.73M |
| Total Stockholders Equity | $510.61M | $307.83M | $-314.49M | $-207.00M | $256.39M |
| Total Equity | $510.61M | $307.83M | $-314.49M | $-207.00M | $256.39M |
| Total Liabilities and Stockholders Equity | $560.38M | $339.89M | $-283.98M | $353.49M | $288.33M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $560.38M | $339.89M | $-283.98M | $353.49M | $288.33M |
| Total Investments | $275.54M | $50.08M | $166.11M | $162.43M | $- |
| Total Debt | $24.61M | $14.67M | $16.12M | $16.45M | $- |
| Net Debt | $-124.73M | $-234.44M | $-202.52M | $-298.98M | $-276.73M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $149.34M | $187.54M | $189.06M | $275.59M | $249.11M | $275.68M | $310.34M | $201.86M | $52.35M | $108.30M | $113.48M | $75.97M | $153.00M | $90.99M | $243.74M | $259.87M | $276.73M | $88.75M | $-49.65M | $49.65M |
| Short Term Investments | $275.54M | $314.35M | $352.88M | $250.32M | $39.12M | $43.99M | $74.03M | $121.89M | $161.20M | $119.42M | $127.60M | $160.18M | $94.78M | $70.69M | $- | $- | $- | $- | $99.30M | $- |
| Cash and Short Term Investments | $424.88M | $501.89M | $541.95M | $525.91M | $288.23M | $319.66M | $310.34M | $201.86M | $213.55M | $227.72M | $241.09M | $236.15M | $247.78M | $161.68M | $243.74M | $259.87M | $276.73M | $88.75M | $49.65M | $49.65M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $47.00K | $791.00K | $1.22M | $965.00K | $1.49M | $896.00K | $- | $978.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $-700.00K | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $10.05M | $8.87M | $10.69M | $9.68M | $8.36M | $8.58M | $7.43M | $6.59M | $6.96M | $9.53M | $10.87M | $13.79M | $8.46M | $6.53M | $7.58M | $3.67M | $4.44M | $1.39M | $- | $1.88M |
| Total Current Assets | $434.93M | $510.76M | $552.63M | $535.59M | $296.59M | $328.24M | $310.34M | $207.04M | $220.51M | $232.48M | $246.52M | $243.05M | $256.28M | $165.73M | $248.75M | $264.50M | $282.66M | $92.54M | $49.65M | $52.51M |
| Property Plant Equipment Net | $40.61M | $41.63M | $29.45M | $30.58M | $31.66M | $32.69M | $33.65M | $34.32M | $35.35M | $35.51M | $34.92M | $32.64M | $28.95M | $8.79M | $5.58M | $5.01M | $5.07M | $4.98M | $- | $5.05M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $80.58M | $48.78M | $35.72M | $62.94M | $10.95M | $- | $- | $1.41M | $4.91M | $11.12M | $20.53M | $48.36M | $67.65M | $65.49M | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $4.26M | $2.86M | $2.32M | $771.00K | $684.00K | $682.00K | $8.51M | $1.26M | $1.08M | $1.05M | $963.00K | $875.00K | $602.00K | $602.00K | $602.00K | $602.00K | $602.00K | $675.00K | $-49.65M | $677.00K |
| Total Non-Current Assets | $125.45M | $93.27M | $67.48M | $94.29M | $43.30M | $33.37M | $42.16M | $36.98M | $41.34M | $47.69M | $56.41M | $81.88M | $97.21M | $74.89M | $6.18M | $5.61M | $5.67M | $5.66M | $-49.65M | $5.73M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $560.38M | $604.03M | $620.12M | $629.88M | $339.89M | $361.61M | $352.50M | $244.02M | $261.85M | $280.16M | $302.94M | $324.93M | $353.49M | $240.62M | $254.93M | $270.11M | $288.33M | $98.19M | $- | $58.23M |
| Account Payables | $4.39M | $2.92M | $3.43M | $4.22M | $3.52M | $4.71M | $3.49M | $2.41M | $3.32M | $1.48M | $3.32M | $2.68M | $4.76M | $3.71M | $1.96M | $1.28M | $1.79M | $1.29M | $- | $1.74M |
| Short Term Debt | $5.64M | $5.09M | $6.39M | $3.17M | $3.15M | $6.25M | $6.21M | $2.68M | $2.65M | $5.27M | $5.19M | $4.07M | $1.23M | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $257.00K | $35.00K | $- | $1.32M | $273.00K | $130.00K | $576.00K | $778.00K | $884.00K | $2.21M | $2.26M | $2.11M | $2.60M | $1.73M | $3.02M | $7.09M | $6.59M | $5.62M | $- | $5.86M |
| Other Current Liabilities | $18.87M | $21.41M | $9.58M | $9.01M | $12.01M | $7.91M | $2.99M | $5.41M | $8.87M | $5.06M | $4.20M | $3.53M | $7.74M | $5.93M | $4.89M | $5.54M | $8.37M | $7.37M | $- | $5.35M |
| Total Current Liabilities | $29.15M | $29.46M | $19.40M | $16.40M | $18.95M | $18.16M | $13.75M | $11.28M | $15.73M | $13.56M | $14.33M | $12.09M | $16.34M | $11.37M | $9.87M | $13.92M | $16.74M | $14.28M | $- | $12.96M |
| Long Term Debt | $18.97M | $19.74M | $10.46M | $11.00M | $11.52M | $12.03M | $12.53M | $13.01M | $13.47M | $13.92M | $14.40M | $14.78M | $15.22M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $1.06M | $- | $1.32M | $1.32M | $972.00K | $1.10M | $847.00K | $884.00K | $1.08M | $1.00M | $1.45M | $1.76M | $2.49M | $3.01M | $2.34M | $11.69M | $13.23M | $11.73M | $- | $13.60M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $369.00K | $369.00K | $212.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $603.00K | $1.87M | $596.00K | $600.00K | $617.00K | $389.00K | $236.00K | $248.00K | $233.00K | $236.00K | $234.00K | $236.00K | $334.00K | $2.10M | $2.08M | $2.08M | $1.97M | $13.76M | $- | $104.65M |
| Total Non-Current Liabilities | $20.63M | $21.61M | $12.37M | $12.92M | $13.11M | $13.52M | $13.61M | $14.14M | $14.78M | $15.16M | $16.09M | $16.78M | $18.04M | $5.11M | $4.42M | $13.77M | $15.20M | $13.76M | $- | $118.25M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $697.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $49.78M | $51.08M | $31.78M | $29.32M | $32.06M | $31.68M | $725.29M | $25.41M | $30.51M | $28.72M | $30.42M | $28.87M | $34.38M | $16.48M | $14.29M | $27.68M | $31.94M | $28.04M | $- | $131.20M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $175.45M | $102.98M | $102.98M |
| Common Stock | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K | $- | $1.00K |
| Retained Earnings | $-576.20M | $-526.52M | $-482.68M | $-447.73M | $-415.33M | $-383.04M | $-372.79M | $-343.17M | $-314.49M | $-287.11M | $-261.42M | $-233.33M | $-207.00M | $-181.91M | $-159.67M | $-152.09M | $-135.68M | $-115.13M | $- | $-79.03M |
| Accumulated Other Comprehensive Income Loss | $229.00K | $- | $-293.00K | $-109.00K | $16.00K | $534.00K | $345.00K | $-270.00K | $-1.20M | $-1.85M | $-1.83M | $-1.42M | $-423.00K | $-195.00K | $- | $0 | $0 | $-175.45M | $-72.97M | $-102.98M |
| Other Total Stockholders Equity | $1.09B | $1.08B | $1.07B | $1.05B | $723.14M | $712.44M | $697.58M | $562.04M | $547.02M | $540.40M | $535.76M | $530.81M | $526.52M | $406.24M | $400.32M | $394.51M | $392.06M | $9.84M | $- | $6.05M |
| Total Stockholders Equity | $510.61M | $552.95M | $588.34M | $600.56M | $307.83M | $329.93M | $-372.79M | $-343.17M | $231.34M | $251.44M | $272.52M | $296.06M | $319.11M | $224.13M | $240.65M | $242.43M | $256.39M | $70.16M | $30.01M | $-72.97M |
| Total Equity | $510.61M | $552.95M | $588.34M | $600.56M | $307.83M | $329.93M | $-372.79M | $-343.17M | $231.34M | $251.44M | $272.52M | $296.06M | $319.11M | $224.13M | $240.65M | $242.43M | $256.39M | $70.16M | $30.01M | $-72.97M |
| Total Liabilities and Stockholders Equity | $560.38M | $604.03M | $620.12M | $629.88M | $339.89M | $361.61M | $352.50M | $-317.76M | $261.85M | $280.16M | $302.94M | $324.93M | $353.49M | $240.62M | $254.93M | $270.11M | $288.33M | $98.19M | $30.01M | $58.23M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $560.38M | $604.03M | $620.12M | $629.88M | $339.89M | $361.61M | $352.50M | $-317.76M | $261.85M | $280.16M | $302.94M | $324.93M | $353.49M | $240.62M | $254.93M | $270.11M | $288.33M | $98.19M | $30.01M | $58.23M |
| Total Investments | $356.12M | $363.13M | $388.60M | $313.26M | $50.08M | $43.99M | $74.03M | $123.29M | $166.11M | $130.54M | $148.14M | $208.54M | $162.43M | $136.18M | $- | $- | $- | $- | $99.30M | $- |
| Total Debt | $24.61M | $24.83M | $13.66M | $14.17M | $14.67M | $15.16M | $15.63M | $15.68M | $16.12M | $16.55M | $17.00M | $16.82M | $16.45M | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-124.73M | $-162.71M | $-175.41M | $-261.42M | $-234.44M | $-260.52M | $-294.71M | $-186.18M | $-36.23M | $-91.75M | $-96.49M | $-59.15M | $-136.55M | $-90.99M | $-243.74M | $-259.87M | $-276.73M | $-88.75M | $49.65M | $-49.65M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-160.87M | $-100.84M | $-107.49M | $-71.32M | $-56.69M |
| Depreciation and Amortization | $6.71M | $5.75M | $3.88M | $3.02M | $1.44M |
| Deferred Income Tax | $- | $- | $- | $- | $20.00K |
| Stock Based Compensation | $26.12M | $19.66M | $17.12M | $13.80M | $4.98M |
| Change in Working Capital | $537.00K | $630.00K | $-1.34M | $-15.53M | $-711.00K |
| Accounts Receivables | $- | $- | $47.00K | $1.44M | $-508.00K |
| Inventory | $- | $- | $- | $-4.54M | $-591.00K |
| Accounts Payables | $871.00K | $896.00K | $-1.64M | $2.29M | $43.00K |
| Other Working Capital | $-334.00K | $-266.00K | $255.00K | $-14.72M | $345.00K |
| Other Non Cash Items | $-7.08M | $-999.00K | $1.14M | $898.00K | $48.00K |
| Net Cash Provided by Operating Activities | $-134.59M | $-75.79M | $-86.69M | $-69.13M | $-50.91M |
| Investments in Property Plant and Equipment | $- | $-2.77M | $-11.54M | $-9.11M | $-1.00M |
| Acquisitions Net | $- | $- | $11.54M | $9.11M | $- |
| Purchases of Investments | $-467.65M | $-54.80M | $-153.31M | $-168.57M | $- |
| Sales Maturities of Investments | $169.00M | $- | $147.80M | $5.00M | $- |
| Other Investing Activities | $-3.79M | $173.29M | $-11.54M | $-9.11M | $-1.00M |
| Net Cash Used for Investing Activities | $-302.44M | $115.72M | $-17.05M | $-172.68M | $-1.00M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $331.41M | $148.34M | $2.73M | $114.30M | $205.66M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.84M | $8.49M | $3.08M | $3.79M | $73.33M |
| Net Cash Used Provided by Financing Activities | $337.25M | $156.83M | $3.08M | $118.09M | $278.98M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-99.77M | $196.76M | $-100.65M | $-123.72M | $227.07M |
| Cash at End of Period | $149.34M | $249.11M | $52.35M | $153.00M | $276.73M |
| Cash at Beginning of Period | $249.11M | $52.35M | $153.00M | $276.73M | $49.65M |
| Operating Cash Flow | $-134.59M | $-75.79M | $-86.69M | $-69.13M | $-50.91M |
| Capital Expenditure | $- | $-2.77M | $-11.54M | $-9.11M | $-1.00M |
| Free Cash Flow | $-134.59M | $-78.56M | $-98.22M | $-78.24M | $-51.91M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-49.67M | $-43.84M | $-34.95M | $-32.40M | $-32.28M | $-10.26M | $-29.62M | $-28.68M | $-27.38M | $-25.69M | $-28.09M | $-26.34M | $-25.08M | $-22.24M | $-7.59M | $-16.41M | $-20.55M | $-7.83M | $-15.15M | $-13.16M |
| Depreciation and Amortization | $1.78M | $1.70M | $1.62M | $1.59M | $1.51M | $1.40M | $1.43M | $1.41M | $1.39M | $879.00K | $831.00K | $782.00K | $1.89M | $382.00K | $370.00K | $381.00K | $371.00K | $369.00K | $359.00K | $344.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-630.00K | $- | $- | $- | $- | $- | $- | $- | $- | $7.00K | $-7.00K | $94.00K | $- | $- | $- | $- |
| Stock Based Compensation | $7.58M | $6.49M | $6.07M | $5.97M | $5.91M | $4.56M | $4.97M | $4.22M | $4.35M | $4.52M | $4.32M | $3.93M | $3.73M | $3.92M | $3.82M | $2.33M | $1.72M | $1.15M | $1.04M | $1.08M |
| Change in Working Capital | $-3.72M | $4.21M | $-688.00K | $-3.52M | $664.00K | $3.10M | $1.36M | $-4.49M | $-358.00K | $-977.00K | $2.54M | $-2.54M | $-3.11M | $2.18M | $-12.82M | $-1.79M | $908.00K | $-7.06M | $7.59M | $-2.15M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $47.00K | $- | $- | $47.00K | $744.00K | $427.00K | $-253.00K | $521.00K | $-590.00K | $-168.00K | $151.00K | $99.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $314.00K | $-5.87M | $1.58M | $426.00K | $-677.00K | $-1.53M | $-2.59M | $2.76M | $770.00K |
| Accounts Payables | $1.46M | $-508.00K | $-786.00K | $703.00K | $-1.09M | $1.37M | $947.00K | $-333.00K | $1.51M | $-1.70M | $226.00K | $-1.68M | $1.66M | $795.00K | $429.00K | $-601.00K | $567.00K | $-2.77M | $2.58M | $-333.00K |
| Other Working Capital | $-5.18M | $4.72M | $98.00K | $-4.22M | $1.75M | $1.73M | $412.00K | $-4.16M | $-1.92M | $720.00K | $2.31M | $-1.22M | $-5.51M | $962.00K | $-12.99M | $-1.71M | $931.00K | $-4.12M | $4.86M | $-1.92M |
| Other Non Cash Items | $-1.84M | $2.05M | $-2.30M | $7.72M | $173.00K | $29.00K | $-205.00K | $-366.00K | $-211.00K | $252.00K | $492.00K | $611.00K | $738.00K | $29.00K | $15.00K | $116.00K | $52.00K | $5.00K | $-2.00K | $13.00K |
| Net Cash Provided by Operating Activities | $-45.86M | $-29.39M | $-30.24M | $-29.09M | $-24.65M | $-1.17M | $-22.07M | $-27.91M | $-22.21M | $-21.02M | $-19.90M | $-23.55M | $-21.84M | $-15.72M | $-16.20M | $-15.37M | $-17.50M | $-13.37M | $-6.17M | $-13.87M |
| Investments in Property Plant and Equipment | $-949.00K | $1.06M | $-349.00K | $-710.00K | $-549.00K | $-405.00K | $-805.00K | $-1.01M | $-1.09M | $-1.96M | $-2.07M | $-6.41M | $-5.10M | $-2.63M | $-737.00K | $-642.00K | $-508.00K | $349.00K | $-120.00K | $-721.00K |
| Acquisitions Net | $- | $- | $- | $- | $49.08M | $- | $-50.09M | $1.01M | $11.54M | $-17.34M | $-59.53M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-57.78M | $-35.79M | $-96.76M | $-277.32M | $-34.65M | $- | $-5.43M | $-14.73M | $100.51M | $-187.94M | $-6.18M | $-59.69M | $-32.20M | $-136.38M | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $65.79M | $64.87M | $23.57M | $14.78M | $28.51M | $30.39M | $55.52M | $58.87M | $-135.19M | $205.28M | $65.72M | $12.00M | $5.00M | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-2.84M | $- | $-710.00K | $-49.08M | $30.39M | $50.09M | $-1.01M | $-11.54M | $17.34M | $59.53M | $-47.70M | $5.00M | $-136.38M | $- | $-642.00K | $-1.00M | $- | $- | $- |
| Net Cash Used for Investing Activities | $7.06M | $27.30M | $-73.54M | $-263.26M | $-6.68M | $29.98M | $49.29M | $43.13M | $-35.78M | $15.37M | $57.47M | $-54.11M | $-32.29M | $-139.01M | $-737.00K | $-642.00K | $-508.00K | $349.00K | $-120.00K | $-721.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $1.00K | $15.69M | $315.72M | $1.00K | $8.98M | $129.72M | $9.65M | $2.73M | $460.00K | $-50.00K | $629.00K | $116.14M | $1.98M | $820.00K | $-847.00K | $205.10M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $601.00K | $567.00K | $1.56M | $3.11M | $4.76M | $1.58M | $799.00K | $1.35M | $2.05M | $460.00K | $-50.00K | $629.00K | $116.14M | $1.98M | $820.00K | $-847.00K | $877.00K | $900.00K | $72.49M | $-389.00K |
| Net Cash Used Provided by Financing Activities | $601.00K | $568.00K | $17.25M | $318.83M | $4.76M | $10.56M | $130.52M | $10.99M | $2.05M | $460.00K | $-50.00K | $629.00K | $116.14M | $1.98M | $820.00K | $-847.00K | $205.98M | $900.00K | $72.49M | $-389.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-38.20M | $-1.52M | $-86.53M | $-84.00K | $-26.57M | $39.37M | $157.74M | $26.22M | $-55.95M | $-5.19M | $37.51M | $-77.03M | $62.01M | $-152.75M | $-16.12M | $-16.86M | $187.97M | $-12.12M | $66.20M | $-14.98M |
| Cash at End of Period | $149.34M | $187.54M | $189.06M | $275.59M | $249.11M | $275.68M | $236.31M | $78.57M | $52.35M | $108.30M | $113.48M | $75.97M | $153.00M | $90.99M | $243.74M | $259.87M | $276.73M | $88.75M | $100.88M | $34.67M |
| Cash at Beginning of Period | $187.54M | $189.06M | $275.59M | $275.68M | $275.68M | $236.31M | $78.57M | $52.35M | $108.30M | $113.48M | $75.97M | $153.00M | $90.99M | $243.74M | $259.87M | $276.73M | $88.75M | $100.88M | $34.67M | $49.65M |
| Operating Cash Flow | $-45.86M | $-29.39M | $-30.24M | $-29.09M | $-24.65M | $-1.17M | $-22.07M | $-27.91M | $-22.21M | $-21.02M | $-19.90M | $-23.55M | $-21.84M | $-15.72M | $-16.20M | $-15.37M | $-17.50M | $-13.37M | $-6.17M | $-13.87M |
| Capital Expenditure | $-949.00K | $1.06M | $-349.00K | $-710.00K | $-549.00K | $-405.00K | $-805.00K | $-1.01M | $-1.09M | $-1.96M | $-2.07M | $-6.41M | $-5.10M | $-2.63M | $-737.00K | $-642.00K | $-508.00K | $349.00K | $-120.00K | $-721.00K |
| Free Cash Flow | $-46.81M | $-28.33M | $-30.59M | $-29.80M | $-25.20M | $-1.58M | $-22.87M | $-28.92M | $-23.31M | $-22.98M | $-21.97M | $-29.96M | $-26.93M | $-18.36M | $-16.94M | $-16.01M | $-18.01M | $-13.02M | $-6.29M | $-14.59M |
4D Molecular Therapeutics Dividends
Explore 4D Molecular Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
4D Molecular Therapeutics News
Read the latest news about 4D Molecular Therapeutics, including recent articles, headlines, and updates.
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings.
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (wet AMD).
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2024 financial results, provided operational highlights and outlined expected upcoming milestones.
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
On Saturday, 4D Molecular Therapeutics FDMT announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population.
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
EMERYVILLE, Calif., Feb. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population. Additional data were provided on the durability of aflibercept expression for up to two years. The data were presented by Dante Pieramici, M.D., in an oral presentation titled “Phase 2b Population Extension Cohort Evaluating 4D-150 in Neovascular Age-Related Macular Degeneration: 52-Week Results” at Angiogenesis, Exudation, and Degeneration 2025.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported third quarter 2024 financial results, provided operational highlights and outlined expected upcoming milestones.
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Inquiry Has Been Launched Into 4D Molecular Therapeutics, Inc. For Securities Law Violations And Affected Shareholders Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for FDMT.